NCT02705625View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

January 28, 2016

Primary Completion Date

May 23, 2017

Study Completion Date

May 23, 2017

Conditions
Osteoarthritis, Knee
Interventions
DRUG

MIV-711

MIV-711 administered orally once daily

DRUG

Placebo

Placebo manufactured to mimic MIV-711 capsule.

Trial Locations (6)

Unknown

MC Comac Medical, Sofia

LCC ARENSIA Exploratory Medicine, Tbilisi

PAREXEL Berlin Early Phase Clinical Unit, Berlin

LCC ARENSIA Exploratory Medicine, Chisinau

SC ARENSIA Exploratory Medicine SRL, Bucharest

University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds

Sponsors

Lead Sponsor

Medivir
All Listed Sponsors
lead

Medivir

INDUSTRY

NCT02705625 - A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients | Biotech Hunter | Biotech Hunter